Jun 10 |
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
|
Jun 7 |
Replimune (REPL) Gains on Positive Data From Melanoma Study
|
Jun 7 |
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
|
Jun 6 |
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
|
Jun 5 |
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
|
Jun 5 |
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
|
Jun 4 |
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
|
Jun 4 |
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
|
Jun 3 |
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
|
Jun 3 |
Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround
|